Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes serious adverse events for all placebos compared with wait‐list or… (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse events for all placebos compared with wait‐list or no treatment (Spontaneous reporting of dichotomous outcomes) (Post‐treatment) · patients with mental health disorders
It is very uncertain whether the intervention changes non‐serious adverse events for all placebos compared with wait‐list… (very low certainty).
1 finding from 1 review
Serious adverse events · people with asthma
Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with hepatic encephalopathy
1 finding from 1 review
Serious adverse events · people with hepatorenal syndrome
Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · people with hepatorenal syndrome
Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate